Immunovant, Inc. (IMVT)
27.22
-1.45
(-5.06%)
USD |
NASDAQ |
May 07, 16:00
27.35
+0.13
(+0.48%)
Pre-Market: 08:27
Immunovant Research and Development Expense (Annual) : 360.92M for March 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Plus Therapeutics, Inc. | 8.379M |
| Resonate Blends, Inc. | -- |
| Viridian Therapeutics, Inc. | 338.47M |
| Nutriband, Inc. | 1.891M |
| Definium Therapeutics, Inc. | 117.66M |